Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs

Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs

Abstract The recent discovery of clinically significant data, alongside novel physiological and pathological occurrences surrounding sacubitril/valsartan (Sac/Val) beyond its approved indications, necessitates an urgent reevaluation of its underlying mechanism of action. In the present investigation...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenjuan Wei, Guangsen Xu, Jiaer Gao, Guiyun Wang, Ye Wang, Caiyan Li, Junwei Zheng, Huiying Lu, Yunyan Lu, Kun Wang, Hongtao Xu, Cong Wang, Xuebo Pan
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	Cardiovascular Diabetology
Subjects:	Sacubitril/Valsartan Fibroblast growth factor 21 Peroxisome proliferation-activated receptor alpha Peroxisome proliferation-activated receptor gamma Myocardial infarction
Online Access:	https://doi.org/10.1186/s12933-025-02627-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PPARα deficiency exacerbates retinal pathological changes and dysfunction in high-fat diet mice
by: Xue Wang, et al.
Published: (2025-06-01)

Bioinformatics analysis of duck PPARα gene structure and function
by: MA Yun, et al.
Published: (2011-07-01)

Ultrasound therapy inhibits knee osteoarthritis progression in rabbits by activating the PPARs pathway: a pilot study
by: Qinglu Luo, et al.
Published: (2025-12-01)

SARTANS OF THE SECOND GENERATION: THERAPEUTIC POTENTIAL EXTENSION
by: S. V. Nedogoda
Published: (2016-01-01)

PPARα regulates YAP protein levels and activity by affecting its ubiquitination modification
by: Wenhong Zhou, et al.
Published: (2025-02-01)

Per- and Polyfluoroalkyl Substances (PFAS) as Emerging Obesogens: Mechanisms, Epidemiological Evidence, and Regulatory Challenges
by: Niya Lewis, et al.
Published: (2024-12-01)

In silico and in vitro investigations reveal pan-PPAR agonist activity and anti-NAFLD efficacy of polydatin by modulating hepatic lipid-energy metabolism
by: Sumit Kumar Mandal, et al.
Published: (2025-07-01)

Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations
by: R. Bortoletto, et al.
Published: (2025-02-01)

Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling
by: Rui-Qiang Qi, et al.
Published: (2024-11-01)

Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies
by: Kira Vordermark, et al.
Published: (2024-12-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Oral administration of pioglitazone inhibits pulmonary hypertension by regulating the gut microbiome and plasma metabolome in male rats
by: Zizhou Zhang, et al.
Published: (2025-01-01)

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

Exploring the Contribution of Single Nucleotide Polymorphisms in FSHR, LHR, PPAR-γ, and INSR Genes to the Pathogenesis of Polycystic Ovary Syndrome: A Case-control Study
by: Mohd Noorjahan Begum, et al.
Published: (2025-07-01)

Healing Effects of Saroglitazar Gel in Thermally Induced Burn in Rats
by: Aram Ibrahim, et al.
Published: (2024-12-01)

Effects and mechanisms of telmisartan on adiponectin receptors in rat renal proximal tubular epithelial cells induced by high glucose
by: BU Xi, et al.
Published: (2019-01-01)

Administration of chiglitazar reverses chronic stress-induced depressive-like symptoms in mice via activation of hippocampal PPARα and BDNF
by: Jiu-Jian Zhou, et al.
Published: (2025-04-01)

Role of neuronal fabp in autophagy and amyloid-β pathology in a Drosophila model of Alzheimer disease
by: Byoungyun Choi, et al.
Published: (2025-12-01)

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9
by: Marcella Palumbo, et al.
Published: (2025-03-01)

Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators
by: Hyun-Joung Lim, et al.
Published: (2024-11-01)

Polysaccharide from Prinsepia utilis Royle maintains the skin barrier by mediating differentiation, lipid metabolism and tight junction of keratinocyte
by: Ying Tu, et al.
Published: (2025-07-01)

Effect of Fenofibrate on Markers of Gut Barrier Function in Dogs With Naturally Occurring Diabetes Mellitus
by: Allison L. O'Kell, et al.
Published: (2025-05-01)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis
by: Gianluca Di Pietro, et al.
Published: (2025-04-01)

Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study
by: Takahiro Kato, et al.
Published: (2025-12-01)

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
by: Stefano Fiorucci, et al.
Published: (2024-09-01)

A multi-omics exploration of PPARG activation in colon cancer: kinases featuring a PPRE sequence within regulatory regions
by: Pritha Saha, et al.
Published: (2025-06-01)

Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01)

Role and its mechanism of micro RNA-130b in puromycin aminonucleoside-induced podocyte injury
by: WANG Wan-peng, et al.
Published: (2020-01-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

Selective Activity of Chrysin-6-<i>C</i>-Fucopyranoside from <i>Cyclanthera pedata</i> Toward Peroxisome Proliferator-Activated Receptor Gamma
by: Marco Zuccolo, et al.
Published: (2025-04-01)

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
by: Alireza Arzhangzadeh, et al.
Published: (2025-05-01)

Real‐world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure
by: Ankeet S. Bhatt, et al.
Published: (2025-06-01)

Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice
by: Sae Nishihara, et al.
Published: (2024-11-01)

Astragalin improved mitochondrial function through AMPK/PGC-1α pathway and alleviated renal injury in diabetic nephropathy
by: Yi Luo, et al.
Published: (2024-11-01)

Synthesis and Antithrombotic Activity Determination of (2-Methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)-thiazole-5-ylmethylsulfanyl]phenoxy)acetic Acid Derivatives
by: D. V. Minin, et al.
Published: (2019-07-01)

Gene co-expression network analysis reveals positive effects of concentrate supplementation on energy metabolism in early-weaned Nellore calves
by: Gustavo Henrique Russo, et al.
Published: (2025-04-01)

PPAR-γ agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro
by: Maryam Noori, et al.
Published: (2024-12-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
by: Nobian Andre, et al.
Published: (2023-12-01)